Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J R Army Med Corps ; 159(3): 167-8, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24109137

RESUMO

Hepatitis E virus (HEV) has a long military association being first discovered during the Soviet occupation of Afghanistan in the 1980s after an outbreak of unexplained hepatitis at a military camp. HEV is now endemic in the UK, and should be considered in all cases of jaundice. The prevalence is high in certain operational areas (28.5% in Afghanistan), and maintenance of integrity of food and water supplies together with scrupulous attention to environmental hygiene remains paramount. Pregnancy confers a much higher risk of fulminant hepatitis, with a mortality rate of up to 25%. Management is usually symptomatic, but ribavirin can be considered in non-pregnant patients with fulminant hepatitis. This narrative review examines the presentations and management of Hepatitis E in military populations.


Assuntos
Hepatite E/diagnóstico , Hepatite E/epidemiologia , Militares , Hepatite E/complicações , Hepatite E/virologia , Vírus da Hepatite E , Humanos , Incidência , Icterícia/virologia , Prevalência
2.
J R Army Med Corps ; 159(3): 169-74, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24109138

RESUMO

Hepatitis B and hepatitis C are prevalent in several areas of the world. Armed Forces personnel may be exposed to these viruses through risk behaviour or ballistic transmission. This article discusses the epidemiology and treatment of these viruses, together with occupational health considerations.


Assuntos
Anticorpos Antivirais/sangue , Hepacivirus/imunologia , Vírus da Hepatite B/imunologia , Hepatite B/tratamento farmacológico , Hepatite C/tratamento farmacológico , Militares , Hepacivirus/genética , Hepatite B/sangue , Hepatite B/epidemiologia , Antígenos E da Hepatite B/sangue , Vírus da Hepatite B/genética , Hepatite C/sangue , Hepatite C/diagnóstico , Hepatite C/epidemiologia , Humanos , Saúde Ocupacional
3.
Transplantation ; 85(8): 1105-11, 2008 Apr 27.
Artigo em Inglês | MEDLINE | ID: mdl-18431229

RESUMO

BACKGROUND: Prophylaxis to prevent recurrent HBV infection in liver transplant (LT) recipients has evolved over time, and we manage patients who receive lamivudine monoprophylaxis, lamivudine with HBV immunoglobulin (HBIg), and lamivudine and adefovir with HBIg. METHODS: Serum was examined with sensitive assays to detect the persistence of HBV, and to identify mutations that might confer resistance to the antiviral prophylaxis. Forty patients were studied, and sera were collected 20 days to 13.3 years after LT. RESULTS: Overall, HBV DNA was detected in serum of 67.5% of patients (8 of 10 of lamivudine monoprophylaxis patients, 15 of 24 of those receiving lamivudine and HBIg, and 4 of 6 of those receiving lamivudine, adefovir and HBIg). Thus, HBV infection persists for most of the patients despite successful prophylaxis after LT. Of those patients with detectable serum HBV DNA, three of eight of the lamivudine monoprophylaxis group had sequences associated with resistance to lamivudine (YMDD mutants), compared with only 1 of 15 of the lamivudine and HBIg cohort. Three of the lamivudine and HBIg cohort had the I126A Hepatitis B surface antigen escape variant. In those serum HBV DNA-positive patients who were receiving lamivudine, adefovir, and HBIg, only one of four had YMDD mutant, and none had Hepatitis B surface antigen escape variants. None of the 40 patients suffered clinical HBV recurrence. CONCLUSIONS: Our observations imply that the selection of resistant virus may be essential, but is not sufficient to cause overt failure of prophylaxis with development of clinical disease. It seems likely that the patients' immune response contributes, at least partially, to the long-term control of infection in these patients.


Assuntos
Vírus da Hepatite B/isolamento & purificação , Hepatite B/cirurgia , Transplante de Fígado , Adenina/análogos & derivados , Adenina/uso terapêutico , Adulto , Idoso , Estudos Transversais , DNA Viral/sangue , Feminino , Hepatite B/prevenção & controle , Hepatite B/virologia , Humanos , Imunoglobulinas/uso terapêutico , Lamivudina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Organofosfonatos/uso terapêutico
4.
Clin Nutr ; 24(2): 229-35, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15784483

RESUMO

BACKGROUND & AIMS: Home Parenteral Nutrition (HPN) is an accepted treatment of intestinal failure but is mostly restricted to a few large specialist centres in the UK. The provision of high-quality HPN is of paramount importance to patients with intestinal failure, but its restriction to large specialist centres limits the number of patients who can receive it. The study aim was to determine if HPN can be effectively administered in a non-specialist centre. METHODS: Adult HPN patients at a single District General Hospital in the United Kingdom were analysed by indications, complications and outcome. RESULTS: 2310 patient weeks of HPN were provided to 23 patients, aged 18-80 years with intestinal failure. Catheter infection rate was 0.315 per patient year, with one patient excluded due to persistent nasal digitation. Patients spent 89.96% of their time at home and 82.6% achieved a Karnowsky Index of 70 (generally self-caring or greater). CONCLUSIONS: HPN can be practised at non-specialist District General Hospital level achieving complication rates comparable to large specialist centres, and this lends weight to the argument for a network model to widen provision beyond large tertiary referral specialist centres in the United Kingdom.


Assuntos
Cateterismo/efeitos adversos , Acessibilidade aos Serviços de Saúde , Enteropatias/terapia , Nutrição Parenteral no Domicílio/normas , Qualidade da Assistência à Saúde , Sepse/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Nutrição Parenteral no Domicílio/efeitos adversos , Nutrição Parenteral no Domicílio/métodos , Sepse/prevenção & controle , Resultado do Tratamento , Reino Unido
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA